Acumen Pharmaceuticals, Inc. (ABOS) Earnings History
Annual and quarterly earnings data from 2019 to 2024
Loading earnings history...
ABOS EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ABOS Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | -456.9% | -551.0% | -510.1% |
Download Data
Export ABOS earnings history in CSV or JSON format
Free sign-in required to download data
Acumen Pharmaceuticals, Inc. (ABOS) Earnings Overview
As of May 8, 2026, Acumen Pharmaceuticals, Inc. (ABOS) reported trailing twelve-month net income of -$133M, reflecting -58.3% year-over-year growth. The company earned $-2.20 per diluted share over the past four quarters.
Looking at the long-term picture, ABOS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2020.
Acumen Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRAX (-$327M net income), ATNM (-$35M net income), SAVA (-$106M net income), ABOS has comparable earnings metrics. Compare ABOS vs PRAX →
ABOS Earnings vs Peers
Earnings metrics vs comparable public companies
ABOS Historical Earnings Data (2019–2024)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$102M | -95.4% | -$114M | $-1.71 | - | - |
| 2023 | -$52M | -22.2% | -$61M | $-1.08 | - | - |
| 2022 | -$43M | +57.4% | -$45M | $-1.06 | - | - |
| 2021 | -$101M | -1273.5% | -$20M | $-2.63 | - | - |
| 2020 | -$7M | +7.4% | -$8M | $-0.26 | -510.1% | -551.0% |
| 2019 | -$8M | - | -$8M | $-0.27 | -465.9% | -459.9% |
See ABOS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABOS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ABOS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonABOS — Frequently Asked Questions
Quick answers to the most common questions about buying ABOS stock.
Is ABOS growing earnings?
ABOS EPS fell to $-2.20, with earnings declining -58.3%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-133M.
What are ABOS's profit margins?
Acumen Pharmaceuticals, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are ABOS's earnings?
ABOS earnings data spans 2019-2024. The declining earnings trend is -58.3% YoY. Historical data enables comparison across business cycles.